Phaseline

Companies › Theratechnologies

Theratechnologies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TH1902
SORT1-targeted peptide-drug conjugate
SORT1Phase 1Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04706962TH1902Phase 1Solid TumorOncologyDec 2025

Targets

SORT1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.